Shenzhen, China
SiBionics, founded in 2015, is a pioneering venture-backed MedTech startup that emphasizes R&D and commercialization of advanced active implantable medical devices and medical imaging artificial intelligence. Headquartered in China, the company also operates branches in Los Angeles, Beijing, and Guangzhou.
The startup has successfully incubated four cornerstone projects: Retinal Prosthesis, Continuous Glucose Monitoring, AI-based Diabetic Retinopathy Screening, and Gastric Cancer Screening. These initiatives underscore SiBionics' commitment to enhancing healthcare across areas like health management, chronic disease management, disease screening, diagnosis, and treatment.
In its latest fundraising effort, SiBionics secured a CNY500.00M Series D investment on 21 December 2022, backed by strategic investors including Shanghai Healthcare Capital, Industrial Securities Capital, Next Capital 嘉程资本, and China New Town Development. With its innovative technologies and strong financial support, SiBionics is well-positioned to drive meaningful advancements in healthcare technology.
